Drug Trial Radar · NCT05967689
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Jul 31, 2023
Primary completion
Aug 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Taiho Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Conditions
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions
TAS6417Drug
Oral tablets
CYP CocktailDrug
Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
Transporter CocktailDrug
Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts 1-4: Objective Response Rate (ORR)Time frame: Up to approximately 2 years
- Dose Optimization Substudy: ORR as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 2 years
Locations
80 sites in 12 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Withdrawn
City of Hope - Duarte
Duarte, California · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Comprehensive Cancer Centers of Nevada - Central Valley - Twain
Las Vegas, Nevada · Recruiting
Memorial Sloan Kettering Cancer Center - Basking Ridge
Basking Ridge, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center - Monmouth
Middletown, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center - Bergen
Montvale, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center - Commack
Commack, New York · Recruiting
Memorial Sloan Kettering Cancer Center - Westchester
Harrison, New York · Recruiting
MSK Cancer Center
Long Island City, New York · Recruiting
Memorial Sloan Kettering Cancer Center - Nassau
Uniondale, New York · Recruiting
Gabrail Cancer and Research Center
Canton, Ohio · Recruiting
Zangmeister Cancer Center
Columbus, Ohio · Withdrawn
The Toledo Clinic Cancer Center
Toledo, Ohio · Withdrawn
SCRI Oncology Partners
Nashville, Tennessee · Withdrawn
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
IDS Pharmacy
Milwaukee, Wisconsin · Recruiting
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia · Recruiting
Genesis Care North Shore
Saint Leonards, New South Wales, Australia · Recruiting
Joondalup Hospital Pharmacy
Joondalup, Western Australia, Australia · Withdrawn
William Osler Health System - Brampton Civic Hospital
Brampton, Canada · Recruiting
Hopital Nord Laennec
Saint-Herblain, France · Recruiting
Nouvel Hôpital Civil
Strasbourg, Aslace, France · Withdrawn
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France · Recruiting
CHU Caen Normandie
Caen, Basse-Normandie, France · Recruiting
Hopital Ambroise Pare
Boulogne-Billancourt, Île-de-France Region, France · Recruiting
Institut Curie
Paris, Île-de-France Region, France · Recruiting
Centre Hospitalier Universitaire Limoges
Limoges, Limousin, France · Recruiting
Hopital Haut Leveque
Pessac, New Aquitaine, France · Recruiting
Hôpital Nord de Marseille
Marseille, Provence-Alpes-Côte d'Azur Region, France · Recruiting
Uniklinik Dresden
Dresden, Germany · Recruiting
UKGM Studienzentrale
Giessen, Germany · Recruiting
UKR Innere Med II Pneumologie
Regensburg, Germany · Withdrawn
Gesundheit Nordhessen Holding AG
Kassel, Hassen, Germany · Recruiting
Queen Mary Hospital
Pok Fu Lam, Hong Kong Island, Hong Kong · Recruiting
Azienda Socio-Sanitaria Territoriale di Cremona
Cremona, Italy · Recruiting
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
Milan, Italy · Recruiting
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy · Recruiting
Ospedale S. Maria delle Croci
Ravenna, Italy · Recruiting
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.